Connection
Cindy O'Bryant to Receptor Protein-Tyrosine Kinases
This is a "connection" page, showing publications Cindy O'Bryant has written about Receptor Protein-Tyrosine Kinases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.459 |
|
|
|
-
O'Bryant CL, Wenger SD, Kim M, Thompson LA. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. Ann Pharmacother. 2013 Feb; 47(2):189-97.
Score: 0.356
-
Wong KM, Noonan S, O'Bryant C, Jimeno A. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer. Drugs Today (Barc). 2015 Mar; 51(3):161-70.
Score: 0.103